Durable Control of Mycosis Fungoides after Sepsis: “Coley's Toxin?” Case Report and Review of the Literature

Mycosis fungoides, along with Sezary syndrome, is the most common subtype of cutaneous T-cell lymphoma. In this report, we present a patient with advanced-stage mycosis fungoides, who after successful treatment of methicillin-resistant Staphylococcus aureus bacteremia had prolonged disease control off systemic therapy. While this may have been due to single-agent gemcitabine, which can result in long remission, we hypothesize that our patient's durable response was in part due to the immune response elicited after treatment of her severe infection.

[1]  J. Scarisbrick,et al.  Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Horwitz,et al.  Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? , 2017, Expert review of hematology.

[3]  Ash A. Alizadeh,et al.  Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study , 2016 .

[4]  M. Millenson,et al.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Pileri,et al.  Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. Weinstock,et al.  Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. , 2007, Archives of dermatology.

[7]  R. Kurzrock,et al.  Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. , 2006, Clinical lymphoma & myeloma.

[8]  M. Offidani,et al.  Long‐term experience with low‐dose interferon‐α and PUVA in the management of early mycosis fungoides , 2005, European journal of haematology.

[9]  M. Girardi,et al.  Mycosis Fungoides and Sezary Syndrome. , 2017, Hematology/oncology clinics of North America.

[10]  David A Jones,et al.  Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. , 2003, Blood.

[11]  S. H. Hoption Cann,et al.  Dr William Coley and tumour regression: a place in history or in the future. , 2003, Postgraduate medical journal.

[12]  S. A. Cann,et al.  Dr William Coley and tumour regression: a place in history or in the future , 2003 .

[13]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[14]  S. Pileri,et al.  Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[16]  P. Mazza,et al.  Is interferon alpha in cutaneous T‐cell lymphoma a treatment of choice? , 1991, British journal of haematology.